Sartorius Aktiengesellschaft (OTCMKTS:SARTF – Get Free Report) announced its quarterly earnings data on Monday. The company reported $1.11 EPS for the quarter, Zacks reports. Sartorius Aktiengesellschaft had a net margin of 2.50% and a return on equity of 7.69%. The company had revenue of $967.37 million during the quarter.
Sartorius Aktiengesellschaft Stock Performance
OTCMKTS:SARTF remained flat at $205.97 during trading hours on Wednesday. The company has a debt-to-equity ratio of 1.17, a current ratio of 2.02 and a quick ratio of 1.13. The firm’s fifty day moving average is $206.55 and its 200 day moving average is $205.79. Sartorius Aktiengesellschaft has a twelve month low of $175.93 and a twelve month high of $313.00.
Analyst Ratings Changes
Several analysts recently issued reports on SARTF shares. Guggenheim raised shares of Sartorius Aktiengesellschaft to a “strong-buy” rating in a research report on Thursday, December 19th. Wolfe Research raised shares of Sartorius Aktiengesellschaft to a “strong-buy” rating in a research report on Thursday, November 14th.
Sartorius Aktiengesellschaft Company Profile
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers.
Featured Articles
- Five stocks we like better than Sartorius Aktiengesellschaft
- How to Invest in the FAANG Stocks
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
- How to Use the MarketBeat Excel Dividend Calculator
- Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Up Nearly 1000%, Can AppLovin Keep Delivering for Investors?
Receive News & Ratings for Sartorius Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.